相关实验视频
Updated: May 9, 2025
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
6.8K
胃肠道瘤个性化免疫疗法:从分子遗传学到成像生物标志物的综合分析
Jian Guan1,2, Xiaoling Gong1, Hanjiang Zeng1
1Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Therapeutic advances in gastroenterology
|April 29, 2025
概括
确定胃肠道 (GI) 瘤免疫治疗反应的可靠生物标志物至关重要. 本综述涵盖了分子,组织病理和成像标记,以预测治疗结果并改善患者的预后.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 医疗成像医学成像
背景情况:
- 胃肠道 (GI) 瘤的免疫疗法领域正在迅速发展.
- 迫切需要可靠的生物标志物来预测治疗结果,并优化肠道瘤的治疗策略.
研究的目的:
- 为提供GI瘤免疫治疗反应的生物标志物的全面概述.
- 探索分子遗传学,组织病理学和成像学方面的进展,以预测治疗结果.
主要方法:
- 对关键的分子生物标志物的审查:微卫星不稳定性,瘤突变负担和编程死亡配体1表达.
- 探索诸如瘤透性淋巴细胞 (CD8+ T 细胞与调节性 T 细胞的比率) 等组织病理学标记物.
- 评估先进的成像技术 (CT,MRI,PET-CT) 用于对瘤生物学和反应进行非侵入性评估.
主要成果:
- 分子生物标志物 (微卫星不稳定性,瘤突变负担,PD-L1) 对于识别对免疫检查点抑制剂的反应者至关重要.
- 瘤透淋巴细胞,特别是CD8+/Treg比率,是免疫治疗反应的显著预测因素.
- 先进的成像技术有助于对瘤生物学和治疗反应进行非侵入性评估.
结论:
- 整合分子和成像数据可以提高患者选择,治疗监测和适应性治疗设计的精度.
- 在更大的队列中验证生物标志物和临床翻译对于推进胃肠道瘤学精准医学至关重要.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:27Tumor Immunotherapy
397
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
397